Deferiprone (100 mg/kg daily for 4 weeks, ingested) demonstrates a neuroprotective effect in a mouse model of tauopathy, the rTg(tauP301L)4510^[6].

Deferiprine (50-200 mg/kg daily, orally for 5-10 days) alleviates nephrotoxicity in a rat model of acute renal failure induced by Cisplatin^[7].

Deferiprone (13.82 and 27.64 mg/kg per day, ingested for 4 weeks) exhibits anti-apoptotic and neuroprotective activities in a rat model of Alzheimer’s disease^[8].

Deferiprone (ranging from 66 to 660 μM, over 48 to 96 hours) significantly inhibits cell proliferation in TRAMP-C2, Myc-CaP, and 22rv1 cells^[1].

At a concentration of 100 μM and up to 192 hours, deferiprone hampers cell migration in the same cell lines^[1].

Deferiprone (100 μM, 24 hours) reduces both the expression and activity of mitochondrial aconitase (m-Acon) in TRAMP-C2, Myc-CaP, and 22rv1 cells^[1].

Deferiprone (up to 1 μM, between 0.5 and 24 hours) lowers free iron levels in thalassemic red blood cells^[2].

Deferiprone (10 minutes) inhibits human platelet aggregation stimulated by arachidonic acid (AA), adenosine diphosphate (ADP), epinephrine, and collagen, with IC50 values of 0.24, 0.25, 3.36, and 3.73 mM, respectively^[3].

Deferiprone (0.1-3.2 μM, 5 minutes) inhibits COX-1 activity with an IC50 of 0.33 μM^[3].

Deferiprone (4 mM, 5 minutes) prevents ADP-induced formation of cAMP^[3].

Deferiprone (156.25 μg/mL, 24 hours) enhances the survival rate and reduces LDH levels, maintaining normal cell morphology in aged fibroblasts^[4].

Deferiprone (25 μM, 6 hours) increases the antibacterial efficacy of conventional antibiotics against S. epidermidis^[5].